Why the study?
What are the steady-state pharmacokinetics of chronic labetalol therapy in hypertensive patients?
What are the steady-state pharmacokinetics of chronic labetalol therapy in hypertensive patients?
Chronic labetalol therapy results in higher steady-state plasma levels than predicted from acute dosing, and patients with lower steady-state levels require higher maintenance doses for blood pressure control.
Answers are grounded in this paper and cite their sources.
Higher steady-state labetalol levels than acute predictions may inform chronic dosing; leaves open prospective validation in hypertension.
1 During chronic treatment of hypertensive patients observed mean steady-state plasma labetalol levels in ten patients were consistently and significantly higher than predicted from initial acute pharmacokinetic analysis. 2 Mean steady-state levels varied from 36 to 183 ng/ml on a chronic dose of 200 mg twice daily. 3 Patients with lower steady-state levels on a fixed dose of labetalol usually required higher maintenance doses to control blood pressure.
No takes yet. Share an insight, caveat, or question.
McNeil et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: